References
- Pui CH, Evans WE. Acute lymphoblastic leukemia. N Engl J Med 1998;339:605–615.
- Nachman JB, Sather HN, Sensel MG, et al Augmented post-induction therapy for children with high-risk acute lymphoblastic leukemia and a slow response to initial therapy. N Engl J Med 1998;338:1663–1671.
- Kantarjian H, Thomas D, O'Brien S, et al Long-term follow-up results of hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone (Hyper-CVAD), a dose-intensive regimen, in adult acute lymphocytic leukemia. Cancer 2004;101:2788–2801.
- Larson RA. Recent clinical trials in acute lymphocytic leukemia by the Cancer and Leukemia Group B. Hematol Oncol Clin North Am 2000;14:1367–1379.
- Durrant IJ, Richards SM, Prentice HG, Goldstone AH. The Medical Research Council trials in adult acute lymphocytic leukemia. Hematol Oncol Clin North Am 2000;14:1327–1352.
- Gökbuget N, Hoelzer D, Arnold R, et al Treatment of Adult ALL according to protocols of the German Multicenter Study Group for Adult ALL (GMALL). Hematol Oncol Clin North Am 2000;14:1307–1325.
- Thiebaut A, Vernant JP, Degos L, et al Adult acute lymphocytic leukemia study testing chemotherapy and autologous and allogeneic transplantation. A follow-up report of the French protocol LALA 87. Hematol Oncol Clin North Am 2000;14:1353–1366.
- Garcia-Manero G, Thomas DA. Salvage therapy for refractory or relapsed acute lymphocytic leukemia. Hematol Oncol Clin North Am 2001;15:163–205.
- Thomas DA, Kantarjian H, Smith TL, et al Primary refractory and relapsed adult acute lymphoblastic leukemia: characteristics, treatment results, and prognosis with salvage therapy. Cancer 1999;86:1216–1230.
- Tavernier E, Boiron JM, Huguet F, et al GET-LALA Group; Swiss Group for Clinical Cancer Research SAKK; Australasian Leukaemia and Lymphoma Group. Outcome of treatment after first relapse in adults with acute lymphoblastic leukemia initially treated by the LALA-94 trial. Leukemia 2007;21:1907–1914.
- Fielding AK, Richards SM, Chopra R, et al Medical Research Council of the United Kingdom Adult ALL Working Party; Eastern Cooperative Oncology Group. Outcome of 609 adults after relapse of acute lymphoblastic leukemia (ALL); an MRC UKALL12/ECOG 2993 study. Blood 2007;109:944–950.
- Jeha S, Kantarjian H. Clofarabine for the treatment of acute lymphoblastic leukemia. Expert Rev Anticancer Ther 2007;7:113–118.
- Jeha S, Gandhi V, Chan KW, et al Clofarabine, a novel nucleoside analog, is active in pediatric patients with advanced leukemia. Blood 2004;103:784–789.
- DeAngelo DJ, Yu D, Johnson JL, et al Nelarabine induces complete remissions in adults with relapsed or refractory T-lineage acute lymphoblastic leukemia or lymphoblastic lymphoma: Cancer and Leukemia Group B study 19801. Blood 2007;109:5136–5142.
- Ottmann OG, Druker BJ, Sawyers CL, et al A phase 2 study of imatinib in patients with relapsed or refractory Philadelphia chromosome-positive acute lymphoid leukemias. Blood 2002;100:1965–1971.
- Ottmann O, Dombret H, Martinelli G, et al Dasatinib induces rapid hematologic and cytogenetic responses in adult patients with Philadelphia chromosome positive acute lymphoblastic leukemia with resistance or intolerance to imatinib: interim results of a phase 2 study. Blood 2007;110:2309–2315.
- Cox DR, Snell EJ. The analysis of binary data. London:Chapman & Hall; 1970. pp 33–43.
- Cox DR. Regression models and life tables. J Stat Soc (B) 1972;34:187–220.
- Topp MS, Goekbuget N, Kufer P, et al Blinatumomab (anti-CD19 BiTE) for targeted therapy of minimal residual disease (MRD) in patients with B precursor acute lymphoblastic leukemia. In: 14th Congress of European Society of Hematology, 2009, Berlin (Abstract 430).